Private Market View

Huiruisen Biotechnology

Hangzhou, China · Founded 2024 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Hyfinity Investments.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 1 names
  • ·Watchlist + deal alerts for Huiruisen Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Huiruisen Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Huiruisen Biotechnology

Manufacturer of biotechnology products intended to advance medical research and healthcare applications. The company offers production of medical devices, cosmetics, and sanitation products, enabling healthcare providers, research institutions, and distributors to access high-quality, compliant products with reliable performance.

Sector
Healthcare
HQ
Hangzhou, China
Founded
2024
Ownership
Privately Held (backing)
PA Mark — not yet priced

Huiruisen Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Huiruisen Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Huiruisen Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.